Print

Evogene Ltd. Collaborations With Bayer CropScience AG and Monsanto Company (MON) Nominated for 2012 Agrow Awards  
10/9/2012 10:09:49 AM

REHOVOT, ISRAEL--(Marketwire - October 09, 2012) -

Evogene Ltd. (TASE: EVGN), a leading developer of improved plant traits for the food, feed and biofuel industries, announced today that its collaborations with Bayer CropScience and Monsanto Company have received two out of the four nominations for the 2012 Agrow Award for Best Industry Collaboration worldwide. The final award will be presented at the annual Agrow Awards ceremony, the most prestigious event for the crop protection industry, next month in London.

The collaboration with Bayer CropScience was initiated in January 2011 and constitutes a multiyear collaboration to accelerate the development and introduction of improved wheat varieties through the utilization of a combination of advanced breeding and state of the art genetic modification methods.

The collaboration with Monsanto was signed in November 2011 and is an extension to the two companies' multiyear research and development collaboration focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization in corn, soybean, cotton and canola.

Ofer Haviv, Evogene's President and CEO, stated: "As a young company currently listed only on the Israeli Tel Aviv Stock Exchange, we are of course very honored and pleased that the joint achievements being accomplished in these collaborations and our rapidly growing role in the worldwide food, feed and fuel industries are being recognized through these two nominations."

About the Agrow Awards
The 2012 Agrow Awards features 15 categories that reward innovation and excellence in diverse areas, ranging from product chemistry and technology, business strategy, to corporate responsibility. The Best Industry Collaboration award recognizes a successful partnership between two companies in the worldwide crop protection or plant biotechnology arena. All forms of collaboration between two parties are eligible, including R&D collaborations, licensing agreements, joint ventures, manufacturing or formulation arrangements, or sales, marketing or distribution collaborations. Eligible partnerships must have been formed within the last two years. The other two nominees in this category for 2012 are the collaborations between Certis USA and Kumiai Chemical and between Makhteshim Agan and ChemChina.

About Evogene
Evogene is a world leading developer of improved plant traits, such as yield and drought tolerance, for a wide diversity of key crops through the use of plant genomics. The company focuses on utilizing its proprietary computational genomic technologies to provide a complete solution for plant trait improvement through combining state of the art biotechnology and advanced breeding methods. Evogene is collaborating with world leading seed companies to introduce its improved plant traits into key commercial crops under milestone and royalty bearing agreements. Evogene's headquarters are in Rehovot, Israel, and its shares are traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


Contact Information
Evogene:
Efrat Barak Zadok
IR&PR Associate
E-mail: Email Contact
Tel: +972-8-931-1940


//-->